Cardiovascular, Renal and Metabolism (CVRM)
Saving lives by seeing the full picture and jointly addressing cardio-renal-metabolic risks
Jump to section:
A World of Close Collaborative Care for CVRM Patients
At AstraZeneca, CVRM (Cardiovascular, Renal and Metabolism) is one of our main therapy areas because science continues to uncover commonalities between metabolism, heart failure, arterial vascular disease and renal disease – four distinct but interrelated areas. With this knowledge, we are daring to do things differently by shifting focus from treating patients with a single disease, to addressing overlapping disease areas and risk factors.
Cardiovascular, renal and metabolic diseases kill up to 20 million people each year1 and despite the close associations between these disease areas, shared risk factors may still often not be diagnosed or addressed2. For example, if you are an adult with diabetes, you could be 1.8 times more likely to be hospitalised for a heart attack than an adult without diabetes3. If we look at diabetes and kidney disease combined, life expectancy can be reduced by up to 15 years for men and 16 years for women4.
We have made it our mission to help protect up to 130 million people from the often-devastating consequences of CVRM diseases by 2025. We work with cardiovascular, renal and diabetes experts from around the world, who are led by science and fuelled by investigation to adapt a proactive, collaborative, and multidisciplinary approach to patient care.
By taking risks in research, science and investigation, we systematically study compounds across the CVRM diseases and in different combinations – striving to create uncharted pathways of clinical exploration. This first-class clinical research and real-world evidence help us understand the interactions between two or more conditions, and how the deterioration of one condition could adversely affect the others. It also sets the stage for our pioneering approach in the fields of disease regression and organ regeneration, putting us a step closer to making science fiction a reality.
Cardiovascular
Renal
Metabolic
Driven by collaboration
We cannot change the future alone. We are actively investing in broader and stronger partnerships with respected academic institutions, research organisations, patient advocacy groups, and healthcare companies. We are paving the way for clinical practice evolution, and we are using close collaboration as our brick foundation.
We make it our responsibility to help healthcare professionals connect the dots, evolve their clinical practice and provide complete, potentially life-saving care for CVRM patients. Our role is to offer healthcare professionals the best possible solutions to enable them to think holistically and work in closer collaboration during everyday care and across individual specialties. Most importantly, it is through partnering with general practitioners that they can protect patients against heart and renal failure, improve health and save the lives of millions of people living with these diseases.
Joslin Diabetes Center
We are collaborating with the Joslin Diabetes Center at the Harvard Medical School to identify novel factors that could enhance pancreatic beta cell mass and function, or reverse beta cell dysfunction, to potentially prevent or stop the progression of diabetes. Three initial projects have been identified, focusing on several key areas including protecting and regenerating the insulin producing beta cells, with the potential for more projects to be added as new compelling science is identified.
Michigan Medicine
To assist with our commitment to developing new therapies for the prevention and treatment of diabetes, obesity and related metabolic disorders, we have entered a research alliance with Michigan Medicine. Our researchers will utilise cutting-edge technologies to study genetic models and identify targets for treatment.
Our focus on unmet needs
Arterial Vascular Disease
There were approximately 111 million cases of ischaemic heart disease globally in 2015, and cardiovascular diseases are the leading cause of death worldwide with about 17.9 million people dying every year.5, 6
Heart Failure
There are 64 million heart failure patients worldwide, with many suffering from at least one other underlying condition such as type-2 diabetes.7,8
Renal
Chronic kidney disease (CKD) can be a complex, debilitating condition with an estimated 200 million adults diagnosed worldwide.9
Metabolic Disease
Diabetes is a growing disease and an enormous global burden that is currently projected to affect more than 629 million people by the year 2045.10
Resources
Helping save lives by jointly addressing cardio-renal-metabolic risks
Watch how our unique science-driven strategy in cardiovascular, renal and metabolism is helping us to complete the picture.
Understanding the common mechanisms and how CVRM diseases interact
Learn more about our ambitious strategy.
Our early-to-late stage pipeline for CVRM
Today, we believe we are the only pharmaceutical company with a full portfolio of potential CVRM solutions. With more than 25 therapies and therapy combinations in our early-to-late stage pipeline, we seek to bring real science to life, combatting conditions like CKD, ACS, and CHF.
MEDI0382
MEDI0382 is a dual-peptide molecule that impacts insulin secretion and glucose homeostasis. It is under development for type-2 diabetes patients and may hold potential for other metabolic diseases.
MEDI5884
MEDI5884 is designed to enhance reverse cholesterol transport and increase functional HDL. Its development is aimed to help prevent secondary CV events after a heart attack and may have potential for primary prevention in high-risk patients.
DapaCare
DapaCare is a clinical programme aimed at better understanding the cardiovascular and renal profile of dapagliflozin in people with and without type-2 diabetes. The programme will enrol nearly 30,000 patients in randomised clinical trials and generate data across a spectrum of people with established cardiovascular disease, cardiovascular risk factors and renal disease, providing evidence on the effects on patient outcomes.
Phase III/LCM Projects: refers to assets that are pivotal in Phase II/III, or that have been submitted for regulatory approval, and may include assets that are now launched in one or more major markets (removed when launched in all applicable major markets).
Cardiovascular, Renal and Metabolism (as at 25 July 2019)
Phase I
Phase I
Phase II
Phase II
Phase III
Phase III
LCM Projects
LCM Projects
Our medicines
We cannot provide detailed information about our prescription medicines on this website, in compliance with regulations. Our medicines are approved in individual countries for specific uses and the information we provide for patients is governed by local regulations. In some cases, health care professionals and patients can visit local AstraZeneca websites to find out more about our medicines. Please note that in some countries we are not allowed to provide very much, or sometimes any, information on our prescription medicines so you should seek alternative trustworthy sources. Always ask a healthcare professional for advice about medicines.
Atacand, Atacand HCT, Atacand Plus
candesartan cilexetil
Brilinta/Brilique
ticagrelor
Bydureon
exenatide
Byetta
exenatide injection
Crestor
rosuvastatin
Farxiga/Forxiga
dapagliflozin
Komboglyze
saxagliptin and metformin HCl
Kombiglyze XR
saxagliptin and metformin XR
Lokelma
Sodium zirconium cyclosilicate
Onglyza
saxagliptin
Plendil, Modip, Splendil, Munobal, Flodil
felodipine
Qtern
dapagliflozin and saxagliptin
Seloken ZOK, Toprol-XL, Betaloc ZOK
metoprolol succinate
Symlin
pramlintide acetate
Tenormin, Tenormine, Prenormine, Atenol
atenolol
XIGDUO
dapagliflozin and metformin HCI
XIGDUO XR
dapagliflozin and metformin HCI extended-release
Zestril
lisinopril dihydrate
Sharing clinical trials information
Sharing clinical trials information
We publish information about the registration and results of all new and ongoing clinical trials for all products in all phases on our dedicated website.
Information about our medicines
Our medicines are approved in individual countries for specific uses. Visit your local AstraZeneca site to find out more.
Latest news
Join AstraZeneca
and help us deliver life changing medicines
Be among our employees who continue to make us an innovation-driven company that stands firmly among the world's leaders in biopharmaceuticals.
References
- Wang H et al. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: A systematic analysis for the Global Burden of Disease Study 2015. The Lancet 2016; 388(10053):1459–544.
- Edelman Intelligence Relevance and barriers amongst EU specialists Survey 2018. Document ID: Z2-0050 | Date of preparation: August 2018 | Date of expiry: July 2020
- Centers for Disease Control and Prevention (CDC). National Diabetes Statistics Report, 2014: Centers for Disease Control and Preventions Division of Diabetes Translation [cited 2018 Jul 25]. Available from: URL: https://www.cdc.gov/diabetes/pdfs/data/2014-report-estimates-of-diabetes-and-its-burden-in-the-united-states.pdf.
- Wen CP et al. Diabetes with early kidney involvement may shorten life expectancy by 16 years. Kidney Int 2017; 92(2):388–96.
- World Health Organization. WHO World Heart Day: Scale up prevention of heart attack and stroke: World Health Organization; 2019 [cited 2019 Feb 19]. Available from: URL: https://www.who.int/cardiovascular_diseases/world-heart-day/en/.
- Roth GA et al. Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015. J Am Coll Cardiol 2017; 70(1):1–25.
- Vos T et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. The Lancet 2017; 390(10100):1211–59.
- Lawson CA et al. Comorbidity health pathways in heart failure patients: A sequences-of-regressions analysis using cross-sectional data from 10,575 patients in the Swedish Heart Failure Registry. PLoS Med 2018; 15(3):e1002540.
- Ojo A. Addressing the global burden of chronic kidney disease through clinical and translational research. Trans Am Clin Climatol Assoc 2014; 125:229-43; discussion 243-6.
- Ogurtsova K et al. IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract 2017; 128:40–50.
Veeva ID: Z4-17494
Date of next review: 07/06/2021